...
首页> 外文期刊>VASA: Zeitschrift fuer Gefarsskrankheiten. Journal for vascular diseases >ANCA-associated vasculitis: diagnosis, clinical characteristics and treatment.
【24h】

ANCA-associated vasculitis: diagnosis, clinical characteristics and treatment.

机译:ANCA相关性血管炎:诊断,临床特征和治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

The primary systemic vasculitides are a group of diseases characterized by an inflammatory process of the vessel walls and classified according to the smallest vessels involved. Small vessel vasculitides comprise the largest subgroup divided into diseases with a pauci-immune vasculitis and ANCA and diseases with deposition of immunoglobulin without ANCA. ANCA-associated systemic vasculitides include Wegener's granulomatosis, microscopic polyangiitis comprising renal-limited vasculitis and Churg-Strauss syndrome. Diagnosis is based on clinical manifestation, ANCA-testing and histology. Beside the role of ANCA as a diagnostic marker many studies and animal models have focused on the pathogenic role. The treatment of ANCA-associated vasculitis has changed from a standardized "Fauci-protocol" to an individualized less toxic strategy taking into consideration disease severity) organ manifestation, age of the patient and individual risk factors (e.g. increased bone marrow toxicity in patients with renal insufficiency). For remission induction patients are sub-grouped according to limited or generalized disease with moderate or severe renal involvement. Thus cyclophosphamide is only used in patients with generalized disease or - regarding Churg-Strauss-syndrome - patients with risk factors. For maintenance of remission azathioprine should be used in most of the patients.
机译:主要的全身性血管炎是一组以血管壁的炎症过程为特征的疾病,并根据涉及的最小血管进行分类。小血管血管炎是最大的亚组,分为亚细小免疫性血管炎和ANCA疾病,以及免疫球蛋白沉积而无ANCA的疾病。与ANCA相关的全身性血管炎包括韦格纳肉芽肿病,包括肾脏有限性血管炎和Churg-Strauss综合征的微观多血管炎。诊断基于临床表现,ANCA测试和组织学。除了ANCA作为诊断标志物的作用外,许多研究和动物模型还集中在致病作用上。考虑到疾病严重程度,器官表现,患者年龄和个体危险因素(例如,肾病患者的骨髓毒性增加),ANCA相关血管炎的治疗已从标准化的“ Fauci方案”变为个体化的毒性较小的策略功能不足)。对于缓解诱导,根据受限或全身性疾病将患者分为中度或重度肾脏受累。因此,环磷酰胺仅用于患有全身性疾病的患者,或就Churg-Strauss综合征而言,适用于具有危险因素的患者。为了维持缓解,大多数患者应使用硫唑嘌呤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号